1:12 PM
 | 
Jul 03, 2018
 |  BC Extra  |  Company News

Novartis returns rights for Aveo's preclinical cachexia program

Novartis AG (SIX:NOVN; NYSE:NVS) will return to Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rights for AV-380 and other related growth differentiation factor 15 (GDF15) inhibitor antibodies, according to an SEC filing.

Aveo granted Novartis exclusive, worldwide rights to the preclinical cachexia program...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >